ImmuCell showed strong financial performance with significant sales growth and gross margin improvement, alongside a successful debt refinancing. However, challenges remain with potential sales softening, FDA approval delays for Re-Tain, and the need to regain customer trust after supply issues.

Company Guidance

In the recent ImmuCell Corporation conference call discussing the unaudited financial results for the second quarter ended June 30, 2025, the company provided several key metrics. Product sales increased by 18% or $972,000 compared to the second quarter of 2024, and by 14% or $1.8 million for the first half of 2025 over the same period in 2024. Additionally, product sales for the trailing 12-month period ending June 30, 2025, rose by 22% or $5.1 million compared to the previous year. Gross margin improvements were noted with an increase to 44% during the second quarter of 2025 from 22% in 2024, and to 43% during the first half of 2025 from 28% in 2024. Adjusted EBITDA also saw significant growth, with figures of $1.4 million, $3.7 million, and $5.3 million for the 3-month, 6-month, and 12-month periods ending June 30, 2025, respectively, contrasting with negative figures in the same periods of 2024. The company also managed to increase cash reserves to $6 million as of June 30, 2025, from $3.8 million at the end of 2024.

Increased Production Capacity for First Defense

ImmuCell completed its investment to increase production capacity for the First Defense product line, supporting $30 million or more in revenue per year.

Significant Sales Growth

Product sales during the second quarter of 2025 increased by 18% compared to the same period in 2024, with a 22% increase in the trailing 12-month period.

Gross Margin Improvement

Gross margin as a percentage of product sales increased significantly to 44% in Q2 2025 from 22% in Q2 2024.

Adjusted EBITDA Turnaround

Adjusted EBITDA showed strong improvement, reaching $1.4 million in Q2 2025, compared to negative $619,000 in Q2 2024.

Debt Refinancing

ImmuCell successfully refinanced a portion of its bank debt, reducing the interest rate and avoiding large balloon payments due in 2026.

Immucell (ICCC) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ICCC Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	- / -	-0.086	―	―	―
Aug 14, 2025	2025 (Q2)	- / 0.06	-0.196	128.57% (+0.25)	―
May 14, 2025	2025 (Q1)	- / 0.16	-0.056	387.50% (+0.22)
Feb 25, 2025	2024 (Q4)	- / 0.06	-0.147	139.46% (+0.20)
Nov 13, 2024	2024 (Q3)	- / -0.09	-0.121	28.93% (+0.04)
Aug 13, 2024	2024 (Q2)	- / -0.20	-0.178	-10.11% (-0.02)
May 14, 2024	2024 (Q1)	- / -0.06	-0.299	81.27% (+0.24)
Feb 27, 2024	2023 (Q4)	- / -0.15	-0.215	31.63% (+0.07)
Nov 13, 2023	2023 (Q3)	- / -0.12	-0.085	-42.35% (-0.04)
Aug 10, 2023	2023 (Q2)	- / -0.18	-0.088	-102.27% (-0.09)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ICCC Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$6.72	$6.10	-9.23%
May 14, 2025	$4.91	$5.30	+7.94%
Feb 25, 2025	$5.10	$5.48	+7.45%
Nov 13, 2024	$3.53	$3.60	+1.98%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Immucell Corp. (ICCC) report earnings?

Immucell Corp. (ICCC) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).

What is Immucell Corp. (ICCC) earnings time?

Immucell Corp. (ICCC) earnings time is at Nov 17, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ICCC EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing